Status asthmaticus: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
No edit summary
Line 8: Line 8:


==Overview==
==Overview==
'''Status asthmaticus''' is an [[Acute (medical)|acute]] exacerbation of [[asthma]] that does not respond to standard [[Bronchodilator|bronchodilator]] and [[corticosteroid]] therapy. Symptoms include [[chest tightness]], [[dyspnea|rapidly progressive dyspnea]], [[cough|non-productive cough]] and [[Wheeze|wheezing]]. Status asthmaticus if left untreated may result in severe [[bronchospasm]], mucus plugging and rapidly develops [[acidosis]] and [[respiratory failure]] as a consequent of [[carbon di oxide]] retention and [[hypoxemia]].
'''Status asthmaticus''' is an medical emergency caused by an [[Acute (medical)|acute]] exacerbation of [[asthma]] that does not respond to standard [[Bronchodilator|bronchodilator]] and [[corticosteroid]] therapy. Symptoms include [[chest tightness]], [[dyspnea|rapidly progressive dyspnea]], [[cough|non-productive cough]] and [[Wheeze|wheezing]]. Status asthmaticus if left untreated may result in severe [[bronchospasm]], mucus plugging and rapidly develops [[acidosis]] and [[respiratory failure]] as a consequent of [[carbon di oxide]] retention and [[hypoxemia]].


==Epidemiology==
==Epidemiology==
Line 43: Line 43:
====Respiratory Examination====
====Respiratory Examination====
=====Inspection=====
=====Inspection=====
*Use of accessory muscles of respiration such as [[sternocleidomastoid]] and [[scalene]] muscles, correlates with the disease severity
*Use of accessory muscles of respiration such as [[sternocleidomastoid]], [[scalene]] and intercostal muscles, correlates with the disease severity
*Intercostal retractions
*Intercostal retractions
*Paradoxical thoraco-abdominal breathing
*Paradoxical thoraco-abdominal breathing
Line 68: Line 68:


===Pulmonary Function Test===
===Pulmonary Function Test===
[[Spirometry#Explanation of common test values in FVC tests|FEV1]] lower than 60% predicted is strongly suggestive of severe airway obstruction
[[Spirometry#Explanation of common test values in FVC tests|FEV1]] '''lower than 60% predicted''' is strongly suggestive of severe airway obstruction.


===ECG===
===ECG===
Line 75: Line 75:
===Imaging Modalities===
===Imaging Modalities===
[[Asthma CT|High-resolution CT]] may reveal several structural changes related to small-airway disease including [[Bronchiectasis|cylindrical bronchiectasis]], bronchial wall thickening, and [[air trapping]].<ref name="pmid1094668">Robards VL, Lubin EN, Medlock TR (1975) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1094668 Renal transplantation and placement of ileal stoma.] ''Urology'' 5 (6):787-9. PMID: [http://pubmed.gov/1094668 1094668]</ref>
[[Asthma CT|High-resolution CT]] may reveal several structural changes related to small-airway disease including [[Bronchiectasis|cylindrical bronchiectasis]], bronchial wall thickening, and [[air trapping]].<ref name="pmid1094668">Robards VL, Lubin EN, Medlock TR (1975) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1094668 Renal transplantation and placement of ileal stoma.] ''Urology'' 5 (6):787-9. PMID: [http://pubmed.gov/1094668 1094668]</ref>
==Stating based on Arterial Blood Gas Analysis==
====Stage 1====
*[[Hyperventilation]] with normal PO<sub>2</sub>
*No [[hypoxemia]]
*Patients may benefit from nebulized [[ipratropium]] used adjunctive to [[Bronchodilator|β2-agonist]] therapy
====Stage 2====
*[[Hyperventilation]] with [[hypoxemia]] (low PO<sub>2</sub> and PCO<sub>2</sub>)
*Patients may require [[corticosteroids]] in addition to [[bronchodilator]] therapy
====Stage 3====
*[[CO2 retention]] due to respiratory muscle fatigue
*Markedly elevated PCO2 levels are an indicator for mechanical ventilation
*Aggressive [[Bronchodilator|β2-agonist]] therapy along with parenteral [[steroids]] and/or [[Bronchodilator#Theophylline|theophylline]] is indicated
====Stage 4====
*Severe [[hypoxia]] with markedly elevated PCO<sub>2</sub>
*[[FEV1]] lower than 20% predicted is suggestive of an impending [[respiratory failure|respiratory arrest]] that may require [[intubation]] and [[mechanical ventilation]]
*Metered-dose inhalation of [[Bronchodilator|β2-agonist]] and [[Bronchodilator#Anticholinergics|anticholinergics]] are recommended. Administration of parenteral [[steroids]] and/or [[Bronchodilator#Theophylline|theophylline]] has also shown to be beneficial. 
==Treatment==
*Initial severity assessment is evaluated using [[Asthma laboratory tests#Arterial Blood Gas|arterial blood gas]] and [[Asthma pulmonary function test|pulmonary function test]] and aggressive therapy is initiated to prevent progression to [[respiratory failure]]
*'''Supplemental [[oxygen]]''' via nasal canula or [[face mask]] is recommended to alleviate severe [[hypoxia]]. Oxygen saturation is maintained above 92% and is monitored using [[Asthma laboratory tests#Pulse Oximetry|pulse Oximetry]] 
*Mainstay drugs for the management include '''nebulized [[Bronchodilator|β2-agonists]]''' such as [[albuterol]], [[salbutamol]] or [[terbutaline]], '''parenteral [[steroids]]''' such as [[hydrocortisone]] or [[prednisolone]] and '''[[Bronchodilator#Theophylline|theophylline]]'''
*[[Bronchodilator#Anticholinergics|Anti-cholinergics]] such as '''[[ipratropium bromide]]''' may be indicated in patients who are unable to tolerate inhaled [[Bronchodilator|β2-agonists]].
*In patients non-responsive to nebulized [[bronchodilator]], '''IV-[[aminophylline]]''' or '''oral-[[Leukotriene antagonist|leukotriene inhibitor]]''' may be used.<ref name="pmid1934839">Press S, Lipkind RS (1991) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1934839 A treatment protocol of the acute asthma patient in a pediatric emergency department.] ''Clin Pediatr (Phila)'' 30 (10):573-7. PMID: [http://pubmed.gov/1934839 1934839]</ref>
*'''Helium with oxygen mixture''' has shown to reduce airway resistance and thereby reduce the work of breathing and also improve [[bronchodilator]] efficacy.
*Use of [[Magnesium sulfide|magnesium sulphate]] administered either IV or nebulized in addition to [[Bronchodilator|β2-agonists]] remains controversial.<ref name="pmid11097697">Scarfone RJ, Loiselle JM, Joffe MD, Mull CC, Stiller S, Thompson K et al. (2000) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11097697 A randomized trial of magnesium in the emergency department treatment of children with asthma.] ''Ann Emerg Med'' 36 (6):572-8. [http://dx.doi.org/10.1067/mem.2000.111060 DOI:10.1067/mem.2000.111060] PMID: [http://pubmed.gov/11097697 11097697]</ref><ref name="pmid12023699">Bessmertny O, DiGregorio RV, Cohen H, Becker E, Looney D, Golden J et al. (2002) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12023699 A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults.] ''Ann Emerg Med'' 39 (6):585-91. PMID: [http://pubmed.gov/12023699 12023699]</ref><ref name="pmid12501154">Glover ML, Machado C, Totapally BR (2002) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12501154 Magnesium sulfate administered via continuous intravenous infusion in pediatric patients with refractory wheezing.] ''J Crit Care'' 17 (4):255-8. [http://dx.doi.org/10.1053/jcrc.2002.36759 DOI:10.1053/jcrc.2002.36759] PMID: [http://pubmed.gov/12501154 12501154]</ref><ref name="pmid15846687">Blitz M, Blitz S, Beasely R, Diner BM, Hughes R, Knopp JA et al. (2005) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15846687 Inhaled magnesium sulfate in the treatment of acute asthma.] ''Cochrane Database Syst Rev''  (2):CD003898. [http://dx.doi.org/10.1002/14651858.CD003898.pub2 DOI:10.1002/14651858.CD003898.pub2] PMID: [http://pubmed.gov/15846687 15846687]</ref>
*'''Non-invasive ventilation''' using [[Positive airway pressure|C-PAP]] or tight-fitting [[Medical ventilator|face mask]] may be used to reduce the work of breathing without intubation.
*'''[[Tracheal intubation|Endotracheal intubation]]''' and '''[[mechanical ventilation]]''' should be used with caution in asthmatics who are non-responsive to medical therapy or non-invasive methods of ventilation, due to the substantial risk of [[barotrauma]]. Common indications include impending [[respiratory failure|respiratory arrest]], [[hypoxia|severe hypoxia]] non-responsive to supplemental [[oxygen]], [[CO2 retention]] with PaCO<sub>2</sub> greater than 50 mmHg, [[acidosis]] and/or altered mental status. 
==Complications==
*[[Pneumothorax]] as a complication of [[mechanical ventilation]]
*Intubation increases the risk of super-imposed infection
==Prevention==
*Compliant to medications
*Avoid [[Asthma risk factors|triggering factors]]


==References==
==References==
Line 86: Line 133:
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Intensive care medicine]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date pulmonology]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 20:30, 27 September 2011

Template:DiseaseDisorder infobox

Asthma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Asthma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Pulmonary Function Test
Bronchial Challenge Test
Exhaled nitric oxide

Treatment

Emergency Management

Medical Therapy

Alternative and Complementary Medicine

Bronchial Thermoplasty

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Status asthmaticus On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Status asthmaticus

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Status asthmaticus

CDC on Status asthmaticus

Status asthmaticus in the news

Blogs on Status asthmaticus

Directions to Hospitals Treating Asthma

Risk calculators and risk factors for Status asthmaticus

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]

Overview

Status asthmaticus is an medical emergency caused by an acute exacerbation of asthma that does not respond to standard bronchodilator and corticosteroid therapy. Symptoms include chest tightness, rapidly progressive dyspnea, non-productive cough and wheezing. Status asthmaticus if left untreated may result in severe bronchospasm, mucus plugging and rapidly develops acidosis and respiratory failure as a consequent of carbon di oxide retention and hypoxemia.

Epidemiology

Approximately 10% of the US population is affected by asthma and an increased prevalence of 60% is observed in all age groups, with status asthmaticus requiring the highest rates of hospitalization.[1]

Predisposing factors

  • Increase use of bronchodilator despite resistance,
  • Frequent exacerbations despite the use of corticosteroids,
  • Despite adhering to therapy, a peak flow rate of less than 10% from baseline,
  • Frequent hospitalization for acute attacks,
  • History of syncope or seizure during an acute asthmatic attack,
  • Oxygen saturation lower than 92% despite supplemental oxygen,
  • Airway obstruction is significantly reduced, resulting in severe impairment of air motion that leads to a silent chest with the absence of wheeze suggestive of an imminent respiratory arrest.

Diagnosis

History and Symptoms

Physical Examination

Vital Signs

General Physical Examination

  • Sit upright with arms extended to support the upper chest (tripod position) that assists the use of accessory muscles of respiration
  • Peak flow rate measurement is a simple bedside method to assess the severity of airway obstruction. A red zone indicates less than 50% of the usual or normal peak flow reading signifying a severe airway obstruction.

Respiratory Examination

Inspection
  • Use of accessory muscles of respiration such as sternocleidomastoid, scalene and intercostal muscles, correlates with the disease severity
  • Intercostal retractions
  • Paradoxical thoraco-abdominal breathing
Auscultation
  • High-pitch prolong polyphonic expiratory wheeze
  • Bilateral crackles
  • Air entry may or may not be reduced depending on the disease severity
  • Absence of wheeze and breath sounds secondary to severe airway obstruction may represent a silent chest which is an ominous sign of imminent respiratory failure.

Cardiovascular Examination

Progressive untreated airway obstruction and increased work of breathing eventually leads to worsening hypoxemia, hypercarbia and increased air trapping with compromised stroke volume that results in bradycardia, hypotension, hypoventilation and subsequent cardiorespiratory arrest.

Neurological Examination

  • Level of consciousness ranges from lethargy, agitation to even loss of consciousness or seizure, secondary to severe airway obstruction, hypoxia and carbon-di-oxide retention.
  • Unable to speak in full sentences

Laboratory Tests

  • Measurement of oxygen saturation by pulse oximetry may be useful to identify patients with acute severe asthma who may rapidly progress to respiratory failure and thereby require more intensive therapy.[2]

Pulmonary Function Test

FEV1 lower than 60% predicted is strongly suggestive of severe airway obstruction.

ECG

The presence of supraventricular tachycardia on ECG should raise a suspicion of theophylline toxicity.

Imaging Modalities

High-resolution CT may reveal several structural changes related to small-airway disease including cylindrical bronchiectasis, bronchial wall thickening, and air trapping.[3]

Stating based on Arterial Blood Gas Analysis

Stage 1

Stage 2

Stage 3

Stage 4

Treatment

  • Helium with oxygen mixture has shown to reduce airway resistance and thereby reduce the work of breathing and also improve bronchodilator efficacy.
  • Non-invasive ventilation using C-PAP or tight-fitting face mask may be used to reduce the work of breathing without intubation.

Complications

Prevention

References

  1. Gorelick M, Scribano PV, Stevens MW, Schultz T, Shults J (2008) Predicting need for hospitalization in acute pediatric asthma. Pediatr Emerg Care 24 (11):735-44. DOI:10.1097/PEC.0b013e31818c268f PMID: 18955910
  2. Overall JE (1975) Rating session. Video taped interviews and BPRS ratings. Psychopharmacol Bull 11 (1):15. PMID: 1121560
  3. Robards VL, Lubin EN, Medlock TR (1975) Renal transplantation and placement of ileal stoma. Urology 5 (6):787-9. PMID: 1094668
  4. Press S, Lipkind RS (1991) A treatment protocol of the acute asthma patient in a pediatric emergency department. Clin Pediatr (Phila) 30 (10):573-7. PMID: 1934839
  5. Scarfone RJ, Loiselle JM, Joffe MD, Mull CC, Stiller S, Thompson K et al. (2000) A randomized trial of magnesium in the emergency department treatment of children with asthma. Ann Emerg Med 36 (6):572-8. DOI:10.1067/mem.2000.111060 PMID: 11097697
  6. Bessmertny O, DiGregorio RV, Cohen H, Becker E, Looney D, Golden J et al. (2002) A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. Ann Emerg Med 39 (6):585-91. PMID: 12023699
  7. Glover ML, Machado C, Totapally BR (2002) Magnesium sulfate administered via continuous intravenous infusion in pediatric patients with refractory wheezing. J Crit Care 17 (4):255-8. DOI:10.1053/jcrc.2002.36759 PMID: 12501154
  8. Blitz M, Blitz S, Beasely R, Diner BM, Hughes R, Knopp JA et al. (2005) Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev (2):CD003898. DOI:10.1002/14651858.CD003898.pub2 PMID: 15846687


Template:WikiDoc Sources